Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Rhythm Pharmaceuticals (RYTM) over the last 10 years, with Q3 2025 value amounting to $211.2 million.

  • Rhythm Pharmaceuticals' Total Liabilities rose 14.94% to $211.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $211.2 million, marking a year-over-year increase of 14.94%. This contributed to the annual value of $227.7 million for FY2024, which is 3972.0% up from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Total Liabilities is $211.2 million, which was up 14.94% from $239.2 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Total Liabilities ranged from a high of $239.2 million in Q2 2025 and a low of $33.6 million during Q3 2021
  • Moreover, its 5-year median value for Total Liabilities was $127.7 million (2023), whereas its average is $136.8 million.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Total Liabilities soared by 22306.02% in 2022 and then increased by 14.94% in 2025.
  • Rhythm Pharmaceuticals' Total Liabilities (Quarter) stood at $45.4 million in 2021, then soared by 160.55% to $118.2 million in 2022, then skyrocketed by 37.87% to $163.0 million in 2023, then surged by 39.72% to $227.7 million in 2024, then fell by 7.26% to $211.2 million in 2025.
  • Its Total Liabilities stands at $211.2 million for Q3 2025, versus $239.2 million for Q2 2025 and $223.6 million for Q1 2025.